Teceleukin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2011
01219892011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Although various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell carcinoma… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2004
2004
  • Hisaaki Akaza
  • Journal of clinical oncology : official journal…
  • 2004
4670 Background: In Japan, the officially recommended dose of interleukin-2 (IL-2) is low as less than one tenth of that in U.S.A… (More)
Is this relevant?
Review
1993
Review
1993
Recombinant interleukin-2 (IL-2) products (e.g. aldesleukin, teceleukin) are nonglycosylated, modified forms of the endogenous… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1991
1991
Fifteen patients with advanced, measurable renal cell carcinoma entered a Phase II clinical trial of interleukin-2 (IL-2… (More)
Is this relevant?
Review
1991
Review
1991
The chemical properties, pharmacology, immunology, pharmacokinetics, clinical trials, adverse effects, and dosage and… (More)
Is this relevant?
1989
1989
Single doses of teceleukin ranging from 0.1 to 30 x 10(6) units were administered to cancer patients as intravenous infusions or… (More)
Is this relevant?